Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (6)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Dumortier, J.
Right arrow Articles by Trillet-Lenoir, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dumortier, J.
Right arrow Articles by Trillet-Lenoir, V.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 11:355-358, 2000
© 2000 European Society for Medical Oncology

other

Endometrial mesodermal mixed tumor occurring after tamoxifen treatment: Report on a new case and review of the literature

J. Dumortier1, G. Freyer1, A. J. Sasco2, L. Frappart3, T. Zénone4, P. Romestaing1 and V. Trillet-Lenoir1,

1Department of Radiotherapy and Oncology, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon Lyon
2Unit of Epidemiology for Cancer Prevention, International Agency for Research on Cancer, and Institut National de la Santé el de la Recherche Médicale Lyon
3Department of Pathology, Hopital Edouard Herriot Lyon, France
4Department of Internal Medicine, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon Lyon, France

Correspondence to: V. Trillet-Lenoir, MD, Medical Oncology Unit, Department of Radiotherapy and Oncology, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, France

Background: Anti oestrogenic treatment is widely used for breast cancer treatment and prevention of recurrence. Because of concomitant estrogenic effects, tamoxifen exerts carcinogenic properties on the endometrium. Although secondary endometrial cancers usually present as pure adenocarcinomas, other types of rare tumors have also been reported.

Patients and methods: Herein we describe the clinical, pathological as well as therapeutic aspects of a new case of endometrial mesodermal mixed tumor occurring after long-term tamoxifen therapy. Results: The present case occured five years after cessation of a five years tamoxifen treatment. The patient failed to respond to doxorubicin and cyclophosphamide when combined to 5-fluorouracil (5-FU), but she reached complete response when the same two drugs were used with carboplatin, suggesting the potential usefullness of platinum derivatives.

Conclusions: A longer latency period might be observed for endometrial mesodermal mixed tumors as compared to adenocarcinomas and could justify a prolonged clinical and ultra-sonographic follow-up of patients during and after tamoxifen treatment. When indicated, chemotherapy might require the use of platinum derivatives in this particular type of secondary tumor.

carcinogenesis, endometrium, tamoxifen


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JNCI J Natl Cancer InstHome page
R. E. Curtis, D. M. Freedman, M. E. Sherman, and J. F. Fraumeni Jr.
Risk of Malignant Mixed Mullerian Tumors After Tamoxifen Therapy for Breast Cancer
J Natl Cancer Inst, January 7, 2004; 96(1): 70 - 74.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.